leisure time -WSS

leisure time

author：leisure time 2025-09-27 23:33:13 - browse：3744

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Ascension's ugly legal battle over care for poor patients in Texas

WSS

A preacher's new calling: Diversifying neuroscience research

With FDA staff opposed to Sarepta therapy, top official intervened

Merck to acquire Harpoon Therapeutics for $680 million

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Nonprofit, backed by Microsoft, to certify AI tools in health care

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

The strategy behind pharma's lawsuits over drug pricing reform

Jerome Adams on the need for new antivirals for Covid

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

After affirmative action ruling, medical educators look to 'holistic review'

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Bright Health sells Medicare Advantage business to Molina

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Sports medicine is finally prioritizing gender equality

What would happen to your eyes if you looked at the solar eclipse?

focus

Physician assistants need a new name. Here's what it should be

Medicare Advantage coverage denials need scrutiny, senators say

Weight bias in eating disorder treatment complicated by new weight loss drugs

STAT's guide to the next generation of CAR

Ask STAT: What do you want to know about ChatGPT in medicine?

Gene therapy denied for Afghan refugee whose father aided U.S.

Wikipedia

Wikipedia

hotspot

hotspot